Bristol Myers: Sustained Improvements in Cardiomyopathy Trial

 Treatment with mavacamten showed sustained improvement in left ventricular outflow tract (LVOT) gradients, New York Heart Association (NYHA) Class and N-terminal pro brain natriuretic peptide (NT-proBNP) levels

At 48 and 84 Weeks, Mavacamten safety was consistent with that seen in the EXPLORER-HCM study

Interim results were presented as a late-breaking clinical trial at the American College of Cardiology’s 71^st Annual Scientific Session

https://www.marketscreener.com/quote/stock/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Squibb-Announces-Data-from-EXPLORER-LTE-Demonstrating-Sustained-Improvements-in-Clinic-39953239/